Rise of accountable care organizations (ACOs) could raise the importance of outpatient pharmacies to life sciences manufacturers
Cardinal Health, which already has a decided emphasis on hospital supply, says that it is targeting outpatient pharmacies as both a growth opportunity for itself, and, by providing better support, a way for healthcare providers to increase their own revenue and profitability. Outpatient pharmacies (which tend to be owned by the healthcare providers, although there are exceptions) are expected to become a more critical part of healthcare as ACOs shape up, and as federal Medicare dollars flow more freely toward the underinsured and uninsured patients under the Affordable Care Act.
As a drug-distribution channel, hospitals represent around 10% of pharmaceutical sales, and outpatient pharmacies are some fraction of that. However, the ACO and bundled-payments (for medical services) schemes that are being set up under healthcare reform may raise the importance of this channel. At the same time, longitudinal patient studies show that many drugs dispensed first in the hospital or as the patient leaves become the default drugs of choice for those patients.
“Fully optimized outpatient pharmacies can also enable qualified hospitals, public health clinics, academic medical centers and state-run outpatient facilities to appropriately participate in federal drug pricing programs, which offer drug discounts to help federally qualified healthcare facilities provide care,” says the company.
The services Cardinal Health will offer include business development analysis, new-pharmacy opening services, outpatient pharmacy management and project implementation programs, according to Jon Giacomin, president of Cardinal Health’s Pharmaceutical Distribution business. ““In our work with thousands of hospital pharmacies across the country, we are seeing that many hospitals are leaving drug savings — and revenues -- on the table because they either don’t operate an outpatient pharmacy at all, or they have one that is not fully optimized,” he notes.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.